226H (ATCC® HB-12592)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  / 

Permits and Restrictions

View Permits

Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Strain

Strain: BALB/c (B cell); BALB/c (myeloma)

Applications
This antibody is specific for the rat subunit integrin alphaD.
It may be used to inhibit inflammation at the site of a central nervous system injury.
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
Derivation
Animals were immunized with purified rat alphaD subunit.
Spleen cells were fused with NS-1 mouse myeloma cells.
Genes Expressed
immunoglobulin; monoclonal antibody; against alphaD subunit of rat beta2 (alphaDbeta2) integrin
Cellular Products
immunoglobulin; monoclonal antibody; against alphaD subunit of rat beta2 (alphaDbeta2) integrin
Comments
Animals were immunized with purified rat alphaD subunit.
Spleen cells were fused with NS-1 mouse myeloma cells.
This antibody is specific for the rat subunit integrin alphaD.
It may be used to inhibit inflammation at the site of a central nervous system injury.
Complete Growth Medium RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate, 85%; heat-inactivated fetal bovine serum, 15%
Subculturing
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Cryopreservation
Culture medium supplemented with an additional 50% heat-inactivated fetal bovine serum and 10% DMSO
Culture Conditions
Temperature: 37.0°C
Isotype IgG1; kappa light chain
Name of Depositor ICOS Corporation
U.S. Patent Number
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC.
References

Gallatin WM, Van der Vieren M. Methods of inhibiting inflammation at the site of a central nervous system injury with alphaD-specific antibodies. US Patent 6,251,395 dated Jun 6 2001

Mabon PJ, et al. Inhibition of monocyte/macrophage migration to a spinal cord injury site by an antibody to the integrin alphaD: a potential new anti-inflammatory treatment. Exp. Neurol. 166: 52-64, 2000. PubMed: 11031083

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Gallatin WM, Van der Vieren M. Methods of inhibiting inflammation at the site of a central nervous system injury with alphaD-specific antibodies. US Patent 6,251,395 dated Jun 6 2001

Mabon PJ, et al. Inhibition of monocyte/macrophage migration to a spinal cord injury site by an antibody to the integrin alphaD: a potential new anti-inflammatory treatment. Exp. Neurol. 166: 52-64, 2000. PubMed: 11031083